RxDoctor Payments Data

Marc Frost, MD

Neurology · Amherst, NYNPI 1841256336

Payments from drug & device makers

$385,761in general payments, 2019–2025

Across 500 payments — averaging $771.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurology Practice Consortium GPO, LLC$321K
  • Livanova USA, Inc.$39K
  • UCB SA$13K
  • AbbVie$2K
  • Inspire Medical Systems, Inc.$2K
  • MDD US Operations, LLC$1K
  • plus $6K from 53 others

What the payments were for

  • Consulting fees$1,1859%
  • Travel & lodging$1,40911%
  • Food & beverage$10,15479%
  • Education$1651%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Neurology Practice Consortium GPO, LLC7$321,484
Livanova USA, Inc.67$38,748
UCB SA6$13,377
AbbVie(2 entities)68$2,368
Inspire Medical Systems, Inc.10$2,081
MDD US Operations, LLC37$1,234
Jazz Pharmaceuticals Inc.40$1,039
UCB, Inc.38$836
SK Life Science, Inc.23$591
Abbott10$304
Collegium Pharmaceutical, Inc.12$220
GE HealthCare23$206
Lundbeck LLC11$198
Axsome Therapeutics, Inc.10$185
Neurelis, Inc.9$174
Scilex Pharmaceuticals Inc.9$163
Averitas Pharma Inc.7$152
Greenwich Biosciences, Inc.8$141
Harmony Biosciences LLC7$139
Teva Pharmaceuticals USA, Inc.8$135
Eisai Inc.7$133
Sumitomo Pharma America, Inc.2$129
Vertex4$112
Supernus Pharmaceuticals, Inc.6$110
Neurocrine Biosciences, Inc.6$104
Neuropace, Inc.1$99
Boston Scientific3$93
Catalyst Pharmaceuticals, Inc.4$93
Avadel CNS Pharmaceuticals, LLC2$86
Johnson & Johnson4$73
AstraZeneca4$72
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC4$64
Kyowa Kirin, Inc.3$64
Pfizer3$60
Azurity Pharmaceuticals, Inc.2$48
Sanofi4$47
Sunovion Pharmaceuticals Inc.2$44
Almatica Pharma LLC2$43
Novartis2$42
Amgen2$39
Arbor Pharmaceuticals, Inc.2$39
Avanir Pharmaceuticals, Inc.2$39
Mallinckrodt Hospital Products Inc.1$34
Alnylam Pharmaceuticals Inc.2$31
Upsher-smith Laboratories LLC2$27
CSL Behring1$26
Takeda Pharmaceuticals U.S.A., Inc.1$26
Corium, LLC1$25
Sanofi-aventis U.S. LLC1$22
Sarepta Therapeutics, Inc.1$21
Biogen1$19
Impel Pharmaceuticals LLC1$19
Impel Pharmaceuticals Inc.1$16
Acadia Pharmaceuticals Inc1$16
Akcea Therapeutics, Inc.1$16
E.r. Squibb & Sons, L.L.C.1$16
Biohaven Pharmaceutical Holding Company Ltd.1$14
Nevro Corp.1$13
Biodelivery Sciences International, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$385,761 in reported general payments places this provider in the 90th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$1,364,967
Medicare patients
718
Services billed
27,519

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpidiolexCannabidiol (Cbd)36$179,573
BriviactBrivaracetam35$68,091
LamictalLamotrigine26$67,277
Rufinamide31$64,275
KeppraLevetiracetam44$53,771
TopamaxTopiramate22$50,235
AptiomEslicarbazepine Acetate13$49,556
XcopriCenobamate23$30,642
Levetiracetam844$28,671
ValtocoDiazepam23$22,877
Carbamazepine ErCarbamazepine117$21,951
FycompaPerampanel14$20,310
Nurtec OdtRimegepant Sulfate16$16,639
Divalproex Sodium142$10,691
TegretolCarbamazepine13$10,637

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact$836$68,09135 claims
UCB SAKeppra$13,377$53,77144 claims
Sunovion Pharmaceuticals Inc.Aptiom$44$49,55613 claims
SK Life Science, Inc.Xcopri$591$30,64223 claims
PfizerNurtec Odt, Dilantin, Dilantin$60$25,39452 claims
Neurelis, Inc.Valtoco$174$22,87723 claims
Eisai Inc.Fycompa$133$20,31014 claims
Upsher-smith Laboratories LLCTopiramate$27$3,476212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,623 neurology providers in New York.

Other neurology in Amherst

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →